Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.
RESTART Collaboration
https://pubmed.ncbi.nlm.nih.gov/31128924/Actively Recruiting
Led by Christian Medical College and Hospital, Ludhiana, India · Updated on 2026-09-24
5676
Participants Needed
33
Research Sites
N/A
Total Duration
Researchers are evaluating the use of antiplatelet therapy, specifically Aspirin 75 mg daily, to prevent major adverse cardiovascular and cerebrovascular events MACE in patients who have survived intracerebral haemorrhage ICH. This Phase 3, randomized, placebo-controlled, triple-blinded clinical trial plans to recruit 5676 patients aged 18 to 99 years across 50 stroke centers in India. The study aims to address the safety and effectiveness of starting antiplatelet monotherapy after ICH, a question not yet resolved by large trials. Participants will be randomly assigned to receive either daily Aspirin 75 mg or a matching placebo, both alongside standard secondary prevention care. The medication and follow-up duration depend on recruitment timing those recruited in the first year will take the medication for up to three years or until an event occurs, while those recruited later will take it for a minimum of six months with matching follow-up. The total trial duration is three years, with recruitment lasting 2.5 years and follow-up continuing until the study ends. The investigational products are centrally manufactured and dispensed yearly at each site. Participants will undergo face-to-face visits every three months to receive the medication and return unused tablets, with monthly phone calls to monitor adherence and detect any events. Brain imaging by CT or MRI will be done as part of routine care at baseline and if events occur. Researchers will collect clinical data, medication adherence, and functional assessments such as the modified Rankin Scale. Safety monitoring includes event adjudication and follow-up until three years or until withdrawal, death, or event occurrence. The primary outcome is the occurrence of MACE over three years.
CONDITIONS
Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
J
Jeyaraj D Pandian, MD, DM
D
Deepti Arora, BHMS, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Christian Medical College and Hospital, Ludhiana, India
Lead Sponsor
Indian Council of Medical Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months to 3 years
Participants receive daily Aspirin 75 mg or placebo alongside standard care for secondary prevention after intracerebral haemorrhage. Medication duration varies based on recruitment timing, from six months up to three years or until an event occurs.
Face-to-face visits every 3 months; monthly phone follow-ups
Duration - Up to 3 years
Participants are monitored through regular visits and phone calls to assess medication adherence, capture any events, and evaluate functional outcomes. Brain imaging may be performed as part of routine care if new events occur.
Face-to-face visits every 3 months; monthly phone follow-ups
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
RESTART Collaboration
https://pubmed.ncbi.nlm.nih.gov/31128924/Mira Katan, Andreas Luft
https://pubmed.ncbi.nlm.nih.gov/29791947/Yi-Sin Wong, Ching-Fang Tsai, Cheung-Ter Ong
https://pubmed.ncbi.nlm.nih.gov/36229641/Tapas Kumar Banerjee, Shyamal Kumar Das
https://pubmed.ncbi.nlm.nih.gov/27011621/Christian Medical College and Hospital, Ludhiana, India
Lead Sponsor
Indian Council of Medical Research
Collaborating Sponsor